1
|
Valdez-Hernández P, Ylhuicatzi-Durán M, Guerrero-Hernández M, Alvarado-Bachmann R, Angulo-Molina D. Intraluminal radiofrequency ablation as stricture management in biliary-enteric anastomosis. Rev Gastroenterol Mex (Engl Ed) 2023; 88:439-440. [PMID: 37858456 DOI: 10.1016/j.rgmxen.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 06/14/2023] [Indexed: 10/21/2023]
Affiliation(s)
| | | | | | | | - D Angulo-Molina
- Departamento de Endoscopia, Centro Médico ABC, Mexico City, Mexico.
| |
Collapse
|
2
|
Valero JG, Matas-Céspedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, Guerrero-Hernández M, Yahiaoui A, Balagué O, Martin S, Capdevila C, Hernández L, Magnano L, Rivas-Delgado A, Tannheimer S, Cid MC, Campo E, López-Guillermo A, Colomer D, Pérez-Galán P. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia 2021; 35:2635-2649. [PMID: 33731849 PMCID: PMC8410584 DOI: 10.1038/s41375-021-01201-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 02/03/2021] [Accepted: 02/18/2021] [Indexed: 01/31/2023]
Abstract
Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy.
Collapse
Affiliation(s)
- Juan Garcia Valero
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain
| | - Alba Matas-Céspedes
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain ,grid.417815.e0000 0004 5929 4381Present Address: Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Fabián Arenas
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain
| | - Vanina Rodriguez
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.415306.50000 0000 9983 6924Present Address: Garvan Institute of Medical Research, Sydney, Australia
| | - Joaquim Carreras
- grid.265061.60000 0001 1516 6626Department of Pathology, Tokai University, School of Medicine, Isehara, Kanagawa Japan
| | - Neus Serrat
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain
| | - Martina Guerrero-Hernández
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.11478.3bPresent Address: Department of Gene Regulation, Stem Cells and Cancer Center for Genomic Regulation (CRG-PRBB), Barcelona, Spain
| | - Anella Yahiaoui
- grid.418227.a0000 0004 0402 1634Gilead Sciences, Inc, Foster City, USA
| | - Olga Balagué
- grid.410458.c0000 0000 9635 9413Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain
| | - Silvia Martin
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain
| | - Cristina Capdevila
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain
| | - Lluis Hernández
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain
| | - Laura Magnano
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.410458.c0000 0000 9635 9413Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain
| | - Alfredo Rivas-Delgado
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.410458.c0000 0000 9635 9413Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain
| | - Stacey Tannheimer
- grid.418227.a0000 0004 0402 1634Gilead Sciences, Inc, Foster City, USA
| | - Maria C. Cid
- Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - Elías Campo
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain ,grid.410458.c0000 0000 9635 9413Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain ,grid.5841.80000 0004 1937 0247University of Barcelona, Medical School, Barcelona, Spain
| | - Armando López-Guillermo
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain ,grid.410458.c0000 0000 9635 9413Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain ,grid.5841.80000 0004 1937 0247University of Barcelona, Medical School, Barcelona, Spain
| | - Dolors Colomer
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain ,grid.410458.c0000 0000 9635 9413Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain ,grid.5841.80000 0004 1937 0247University of Barcelona, Medical School, Barcelona, Spain
| | - Patricia Pérez-Galán
- grid.10403.36Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain
| |
Collapse
|
3
|
Serrat N, Guerrero-Hernández M, Matas-Céspedes A, Yahiaoui A, Valero JG, Nadeu F, Clot G, Di Re M, Corbera-Bellalta M, Magnano L, Rivas-Delgado A, Enjuanes A, Beà S, Cid MC, Campo E, Montero J, Hodson DJ, López-Guillermo A, Colomer D, Tannheimer S, Pérez-Galán P. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Adv 2020; 4:4217-4231. [PMID: 32898249 PMCID: PMC7479943 DOI: 10.1182/bloodadvances.2020001584] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Accepted: 07/23/2020] [Indexed: 12/17/2022] Open
Abstract
Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the immunomodulatory consequences of phosphatidylinositol 3-kinase δ (PI3Kδ) inhibition, biomarkers of response, and potential combinatorial therapies in FL remain to be established. Using ex vivo cocultures of FL patient biopsies and follicular dendritic cells (FDCs) to mimic the germinal center (n = 42), we uncovered that PI3Kδ inhibition interferes with FDC-induced genes related to angiogenesis, extracellular matrix formation, and transendothelial migration in a subset of FL samples, defining an 18-gene signature fingerprint of idelalisib sensitivity. A common hallmark of idelalisib found in all FL cases was its interference with the CD40/CD40L pathway and induced proliferation, together with the downregulation of proteins crucial for B-T-cell synapses, leading to an inefficient cross talk between FL cells and the supportive T-follicular helper cells (TFH). Moreover, idelalisib downmodulates the chemokine CCL22, hampering the recruitment of TFH and immunosupressive T-regulatory cells to the FL niche, leading to a less supportive and tolerogenic immune microenvironment. Finally, using BH3 profiling, we uncovered that FL-FDC and FL-macrophage cocultures augment tumor addiction to BCL-XL and MCL-1 or BFL-1, respectively, limiting the cytotoxic activity of the BCL-2 inhibitor venetoclax. Idelalisib restored FL dependence on BCL-2 and venetoclax activity. In summary, idelalisib exhibits a patient-dependent activity toward angiogenesis and lymphoma dissemination. In all FL cases, idelalisib exerts a general reshaping of the FL immune microenvironment and restores dependence on BCL-2, predisposing FL to cell death, providing a mechanistic rationale for investigating the combination of PI3Kδ inhibitors and venetoclax in clinical trials.
Collapse
Affiliation(s)
- Neus Serrat
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Martina Guerrero-Hernández
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Alba Matas-Céspedes
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Anella Yahiaoui
- Department of Biomarker Sciences, Gilead Sciences, Inc., Seattle, WA
| | - Juan G Valero
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Ferran Nadeu
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Guillem Clot
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Miriam Di Re
- Department of Haematology, Wellcome Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom
- Department of Haematology, University of Cambridge, Cambridge, United Kingdom
| | - Marc Corbera-Bellalta
- Vasculitis Research Unit, Department of Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS-CRB CELLEX), Barcelona, Spain
| | - Laura Magnano
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
- Department of Hematology and
| | - Alfredo Rivas-Delgado
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
- Department of Hematology and
| | - Anna Enjuanes
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Silvia Beà
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| | - Maria C Cid
- Vasculitis Research Unit, Department of Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS-CRB CELLEX), Barcelona, Spain
| | - Elías Campo
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
- Hematopathology Unit, Department of Pathology, Hospital Clínic-IDIBAPS, Barcelona, Spain; and
| | - Joan Montero
- Department of Nanobioengineering, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | - Daniel J Hodson
- Department of Haematology, Wellcome Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom
- Department of Haematology, University of Cambridge, Cambridge, United Kingdom
| | - Armando López-Guillermo
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
- Department of Hematology and
| | - Dolors Colomer
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
- Hematopathology Unit, Department of Pathology, Hospital Clínic-IDIBAPS, Barcelona, Spain; and
| | - Stacey Tannheimer
- Department of Biomarker Sciences, Gilead Sciences, Inc., Seattle, WA
| | - Patricia Pérez-Galán
- Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red-Oncología, Madrid, Spain
| |
Collapse
|
4
|
Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G, Guerrero-Hernández M, Rodríguez V, Soldini D, Valera A, Moros A, Climent F, González-Barca E, Mercadal S, Arenillas L, Calvo X, Mate JL, Gutiérrez-García G, Casanova I, Mangues R, Sanjuan-Pla A, Bueno C, Menéndez P, Martínez A, Colomer D, Tejedor RE, Teixidó J, Campo E, López-Guillermo A, Borrell JI, Colomo L, Pérez-Galán P, Roué G. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica 2018; 104:778-788. [PMID: 29954928 PMCID: PMC6442946 DOI: 10.3324/haematol.2017.180505] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Accepted: 06/25/2018] [Indexed: 01/15/2023] Open
Abstract
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biological relevance in this disease remains underexplored. In a homogeneous set of 52 biopsies from patients, an antibody-based cytokine array showed that tissue levels of CXCL12 correlated with high microvessel density and bone marrow involvement at diagnosis, supporting a role for the CXCL12-CXCR4 axis in disease progression. We then identified the tetra-amine IQS-01.01RS as a potent inverse agonist of the receptor, preventing CXCL12-mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines and primary cultures, with superior mobilizing properties in vivo than those of the standard agent. IQS-01.01RS activity was associated with downregulation of p-AKT, p-ERK1/2 and destabilization of MYC, allowing a synergistic interaction with the bromodomain and extra-terminal domain inhibitor, CPI203. In a xenotransplant model of diffuse large B-cell lymphoma, the combination of IQS-01.01RS and CPI203 decreased tumor burden through MYC and p-AKT downregulation, and enhanced the induction of apoptosis. Thus, our results point out an emerging role of CXCL12-CXCR4 in the pathogenesis of diffuse large B-cell lymphoma and support the simultaneous targeting of CXCR4 and bromodomain proteins as a promising, rationale-based strategy for the treatment of this disease.
Collapse
Affiliation(s)
- Clara Recasens-Zorzo
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | | | - Paolo Petazzi
- Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona
| | - Laia Ros-Blanco
- Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
| | - Anna Esteve-Arenys
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Guillem Clot
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Martina Guerrero-Hernández
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Vanina Rodríguez
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Davide Soldini
- Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
| | - Alexandra Valera
- Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
| | - Alexandra Moros
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Fina Climent
- Pathology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat
| | - Eva González-Barca
- Institut Catalá d'Oncología, Hospital Duran I Reynals, L'Hospitalet de Llobregat
| | - Santiago Mercadal
- Institut Catalá d'Oncología, Hospital Duran I Reynals, L'Hospitalet de Llobregat
| | | | - Xavier Calvo
- Pathology Department, IMIM, Hospital del Mar, Barcelona
| | - José Luís Mate
- Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona
| | | | - Isolda Casanova
- Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.,Grup d'Oncogènesi i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona
| | - Ramón Mangues
- Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.,Grup d'Oncogènesi i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona
| | | | - Clara Bueno
- Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona
| | - Pablo Menéndez
- Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.,Institucio Catalana de Recerca I Estudis Avançats (ICREA), CIBERONC, Barcelona
| | - Antonio Martínez
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.,Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
| | - Dolors Colomer
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.,Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
| | - Roger Estrada Tejedor
- Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
| | - Jordi Teixidó
- Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
| | - Elias Campo
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.,Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
| | - Armando López-Guillermo
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.,Department of Hematology, Hospital Clinic, Barcelona
| | - José Ignacio Borrell
- Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
| | - Luis Colomo
- Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.,Pathology Department, IMIM, Hospital del Mar, Barcelona
| | - Patricia Pérez-Galán
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
| | - Gaël Roué
- Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona .,Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
5
|
Recasens-Zorzo C, Cardesa-Salzmann T, Ros-Blanco L, Esteve-Arenys A, Clot G, Guerrero-Hernández M, Valera A, Moros A, Gutierrez G, Casanova I, Mangues R, Sanjuan A, Menéndez P, Rodriguez V, Martínez A, Jares P, Colomer D, Teixidó J, Borrell JI, Campo E, López-Guillermo A, Colomo L, Pérez-Galán P, Roué G. Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-2169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Constitutive activation of CXCR4, a chemokine receptor commonly overexpressed in cancer, is associated with tumor progression, invasion, and chemotherapy resistance. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma (DLBCL), its biological relevance remains underexplored as the evolution of the malignant clone has been traditionally thought to rely mainly on microenvironment-independent factors, including MYC. To evaluate a possible interplay between CXCR4 and MYC signaling in DLBCL we have analyzed the expression of CXCR4 and its ligand CXCL12 in tissue biopsies of a homogeneous cohort of 86 patients with de novo DLBCL, and correlated it with clinico-pathological characteristics and gene expression profiling. We found that co-expression of CXCL12 and CXCR4 was associated with an inferior overall survival when compared to the sole expression of CXCR4 (p=0.017). An ELISA-based array covering 175 human cytokines further showed that tissue levels of CXCL12 best correlated with high microvessel density (p=0.02) pointing out a role for both CXCR4 and CXCL12 in DLBCL tumor aggressiveness. In support of the established role of nuclear CXCR4 on tumor metastasis, abundant nuclear CXCR4 was detected in DLBCL primary tumors and cell lines compared to normal tonsils. This feature was significantly associated with the migratory potential of the tumor cells, thus suggesting CXCR4 as a potential therapeutic target to hamper lymphoma cell dissemination. In silico and in vitro screening of a CXCR4 inhibitor (CXCR4i) library further identified the tetra-amine IQS-01.01 as a potent inhibitor of CXCR4 nuclear translocation. IQS-01.01 prevented CXCL12-mediated chemotaxis and triggered apoptosis in a panel of 14 DLBCL cell lines and primary cells, with improved pharmacological properties than the standard CXCR4i, AMD3100. Mechanistically, IQS-01.01-mediated blockage of CXCR4 signaling was associated with downregulation of p-AKT, p-ERK1/2 and MYC. The combined use of IQS-01.01 with the BET bromodomain inhibitor CPI203 exerted a synergistic cytotoxic effect in DLBCL cell lines in vitro (mean combination index: 0.6±0.2). In a xenotransplant model of DLBCL the IQS-01.01/CPI203 combination decreased tumor burden (p=0.004) through prevention of CXCR4 nuclear import and MYC downregulation, resulting in a synergistic apoptosis induction. Our results point out an emerging role of nuclear CXCR4 in the pathogenesis of DLBCL and support the simultaneous targeting of CXCR4 and BET bromodomain as a promising, rationale-based strategy for DLBCL.
Citation Format: Clara Recasens-Zorzo, Teresa Cardesa-Salzmann, Laia Ros-Blanco, Anna Esteve-Arenys, Guillem Clot, Martina Guerrero-Hernández, Alejandra Valera, Alejandra Moros, Gonzalo Gutierrez, Isolda Casanova, Ramón Mangues, Alejandra Sanjuan, Pablo Menéndez, Vanina Rodriguez, Antonio Martínez, Pedro Jares, Dolors Colomer, Jordi Teixidó, José Ignacio Borrell, Elias Campo, Armando López-Guillermo, Luís Colomo, Patricia Pérez-Galán, Gaël Roué. Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2169. doi:10.1158/1538-7445.AM2017-2169
Collapse
Affiliation(s)
- Clara Recasens-Zorzo
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | - Laia Ros-Blanco
- 3Institut Químic de Sarrià, Universitat Ramón Llull, Barcelona, Spain
| | - Anna Esteve-Arenys
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Guillem Clot
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | - Alejandra Moros
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | - Isolda Casanova
- 5Institut d'Investigacions Biomèdiques-Sant Pau (IIB-Sant Pau), Barcelona, Spain
| | - Ramón Mangues
- 5Institut d'Investigacions Biomèdiques-Sant Pau (IIB-Sant Pau), Barcelona, Spain
| | - Alejandra Sanjuan
- 6Josep Carreras Leukemia Research Institute, University of Barcelona, Barcelona, Spain
| | - Pablo Menéndez
- 6Josep Carreras Leukemia Research Institute, University of Barcelona, Barcelona, Spain
| | - Vanina Rodriguez
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | | | - Jordi Teixidó
- 3Institut Químic de Sarrià, Universitat Ramón Llull, Barcelona, Spain
| | | | | | | | | | - Patricia Pérez-Galán
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Gaël Roué
- 1Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
6
|
Macías-Vidal J, Guerrero-Hernández M, Estanyol JM, Aguado C, Knecht E, Coll MJ, Bachs O. Identification of lysosomal Npc1-binding proteins: Cathepsin D activity is regulated by NPC1. Proteomics 2015; 16:150-8. [PMID: 26507101 DOI: 10.1002/pmic.201500110] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Revised: 09/14/2015] [Accepted: 10/14/2015] [Indexed: 11/09/2022]
Abstract
Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder, characterized by severe neurodegeneration. It is mostly produced by mutations in the NPC1 gene, encoding for a protein of the late endosomes/lysosomes membrane, involved in cholesterol metabolism. However, the specific role of this protein in NPC disease still remains unknown. We aimed to identify Npc1-binding proteins in order to define new putative NPC1 lysosomal functions. By affinity chromatography using an Npc1 peptide (amino acids 1032-1066 of loop I), as bait, we fished 31 lysosomal proteins subsequently identified by LC-MS/MS. Most of them were involved in proteolysis and lipid catabolism and included the protease cathepsin D. Cathepsin D and NPC1 interaction was validated by immunoprecipitation and the functional relevance of this interaction was studied. We found that fibroblasts from NPC patients with low levels of NPC1 protein have high amounts of procathepsin D but reduced quantities of the mature protein, thus showing a diminished cathepsin D activity. The increase of NPC1 protein levels in NPC cells by treatment with the proteasome inhibitor bortezomib, induced an elevation of cathepsin D activity. All these results suggest a new lysosomal function of NPC1 as a regulator of cathepsin D processing and activity.
Collapse
Affiliation(s)
- Judit Macías-Vidal
- Secció d'Errors Congènits del Metabolisme (IBC), Servei de Bioquímica i Genètica Molecular, Hospital Clínic, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Madrid, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | - Josep Maria Estanyol
- Proteomic Unit, Centres Científics i Tecnològics, University of Barcelona, Barcelona, Spain
| | - Carmen Aguado
- CIBER de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratory of Cellular Biology, Centro de Investigación Príncipe Felipe, Valencia, Spain
| | - Erwin Knecht
- CIBER de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratory of Cellular Biology, Centro de Investigación Príncipe Felipe, Valencia, Spain
| | - Maria Josep Coll
- Secció d'Errors Congènits del Metabolisme (IBC), Servei de Bioquímica i Genètica Molecular, Hospital Clínic, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Madrid, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Oriol Bachs
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Cell Biology, Immunology and Neurosciences, University of Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Sánchez-Pérez MA, Luque-de León E, Muñoz-Juárez M, Moreno-Paquentin E, Cordera-González de Cosio F, Guerrero-Hernández M, Benítez-Tress Faez P, Cárdenas-Salomón CM. Acute epiploic appendagitis. Report of three cases. Rev Gastroenterol Mex 2010; 75:195-198. [PMID: 20615791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Primary epiploic appendagitis is a very rare condition that results from acute inflammation of an epiploic appendix. Clinical presentation is non-specific, and many times can mimic acute abdomen. When the diagnosis of epiploic appendagitis is made, conservative treatment must be initiated to avoid unnecessary surgery. We report three cases of acute epiploic appendagitis which were diagnosed by imaging and were managed conservatively with good clinical outcome.
Collapse
Affiliation(s)
- M A Sánchez-Pérez
- Department of General Surgery, American British Cowdray Medical Center, Mexico City, Mexico.
| | | | | | | | | | | | | | | |
Collapse
|